Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

406P - Anti-PD-1 versus anti-PD-L1 inhibitors in first-line therapy non-small-cell lung cancer: A systematic review and meta-analysis

Date

22 Nov 2020

Session

e-Poster Display Session

Topics

Targeted Therapy

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Angelo Brito

Citation

Annals of Oncology (2020) 31 (suppl_6): S1386-S1406. 10.1016/annonc/annonc367

Authors

A.B.C. Brito1, M.P.G. Camandaroba1, V.C.C. de Lima2

Author affiliations

  • 1 Clinical Oncology, AC Camargo Cancer Center, 01525-001-000 - São Paulo/BR
  • 2 Clinical Oncology, AC Camargo Cancer Center, 01525-001 - São Paulo/BR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 406P

Background

Due to the increasing number of trials with immune checkpoint inhibitors (ICI) in first line therapy of non–small cell lung cancer (NSCLC), we performed a systematic review and meta-analyses about the differences between anti PD-1 and PD-L1 in naïve-treatment NSCLC patients through adjusted indirect analysis to minimize the potential bias regarding overall survival (OS), progression free survival (PFS), overall response rate (ORR) and grade 3-5 adverse event (AE).

Methods

We included studies published until May 30 2020. Applicable terms, such as “lung cancer AND first line AND immunotherapy OR PD-1 OR PL-D1,” were used. Primary outcomes were OS, PFS, ORR and grade 3-5 AE. We used the random-effects model to generate pooled estimates for proportions. Meta-analyses using pooled risk ratios were performed for binary outcomes from comparative studies with the random effect model. As there are no studies with direct analyzes between PD-1 and PD-L1 treatments, we carry out indirect data analyzes using the Excel spreadsheet. All analyses were performed by REVMAN version 5.0.

Results

Thirteen studies met our eligibility criteria, including 7673 patients (4077 cases in experimental and 3596 cases in control group). Six trials investigated ICI in monotherapy (four of them with anti-PD-1 and three with anti-PD-L1) and seven trials investigated ICI-chemotherapy combination; three used Pembrolizumabe and four used Atezolizumabe. Related to prognosis, in the ICI-chemotherapy combination group, anti-PD-1 were associated with better OS (P=0.02) and PFS (P=0.03) compared to anti-PD-L1. In monotherapy, there was no statistical difference between the use of anti-PD-1 and anti-PD-L1 for OS and PFS. Regarding ORR and toxicity, in the ICI-chemotherapy combination group, anti-PD-1 was associated with a trand better ORR (p=0.12) and less frequent grade 3-5 AE compared to the use of anti-PD-L1. In monotherapy, no statistical difference between the use of anti-PD-1 and anti-PD-L1 was observed.

Conclusions

Our study suggests that the combination of anti-PD-1 and chemotherapy is superior to anti-PD-L1 + chemotherapy in 1st line NSCLC therapy; in monotherapy both strategies appear to be similar.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.